Multiple Myeloma Market Size 2020 | North America, Europe & Asia Pacific Regions to Dominate the Global Industry

ankit pittewar

The global multiple myeloma market size is projected to reach USD 31 billion by the end of 2026. The high prevalence of the disease will emerge in favor of the companies operating in the market. According to a report published by Fortune Business Insights, titled “Multiple Myeloma Market Size, Share & Industry Analysis, By Drug Class (Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies), and Regional Forecast, 2019-2026,” the market was worth USD 19.48 billion in 2018 and will exhibit a CAGR of 6.0% during the forecast period, 2019-2026.

Highlights of the Report:

In-depth analysis of various insights, namely, Multiple Myeloma Market trends, growth drivers, opportunities, and other related challenges.
Comprehensive details of key market players, their core competencies, and Multiple Myeloma Market share.
The potency of suppliers and buyers to make better business decisions.
Lists out the market size in terms of volume.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/multiple-myeloma-market-102693

Detailed Table of Content:

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. Prevalence of Multiple Myeloma - by Key Countries - 2018
2. Pipeline Analysis
3. Key Industry Developments
4. Regulatory Scenario, by Key Regions
5. Analysis Of Economic Burden of Multiple Myeloma Treatment
6. New Product Launches
7. Overview of Emerging Treatments for Multiple Myeloma
Global Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country
  1. U.S.
  2. Canada
Europe Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia pacific Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Multiple Myeloma Market Analysis, Insights and Forecast, 2015-2026
1. Key Findings / Summary
2. Market Analysis – By Drug Class
  1. Immunomodulators
  2. Proteasome Inhibitor
  3. Anti-CD38 Monoclonal Antibody
  4. Alkylating Agents
  5. Others
3. Market Analysis – By Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies & Drug Stores
  3. Online Pharmacies
4. Market Analysis – By Country/ sub-region
  1. GCC Countries
  2. South Africa
  3. Rest of Middle East & Africa

Continued...

KEY QUESTIONS ANSWERED:

What is the market size and growth rate of the global and regional market by various segments?
What is the market size and growth rate of the market for selective countries?
Which region or sub-segment is expected to drive the market in the forecast period?
What Factors are estimated to drive and restrain the Multiple Myeloma Market growth?
What are the key technological and market trends shaping the market?
What are the key opportunities in the market?
What are the key companies operating in the market?
Which company accounted for the highest market share?

Blood Glucose Monitoring Systems Market

Electrophysiology Devices Market

mHealth Apps Market

ankit pittewar

Multiple Myeloma Market Top Players, Size, Share, Opportunities, Revenue and Growth

Nidz B 2022-02-16

Estimations about the CAGR value for specific forecast period, market drivers, market restraints, and competitive strategies are assessed in this Multiple Myeloma Market report. The global multiple myeloma market size stood at USD 19. Historical, current and projected market size in terms of volume and valueRecent industry trends and developmentsCompetitive landscape of Multiple Myeloma MarketStrategies of key players and product offeringsPotential and niche segments/regions exhibiting promising market growthDrivers & RestraintsOne of the critical market drivers of the global market is the increased prevalence of numerous forms of blood cancers which also includes multiple myeloma. Key players covered in the global Multiple Myeloma Market research report:Takeda Pharmaceutical Company LimitedNovartis AGTeva Pharmaceutical Industries Ltd. Major Table of Contents for Multiple Myeloma Market Research Report:IntroductionExecutive SummaryMarket DynamicsKey Market Growth InsightsGlobal Market Analysis, Insights and Forecast, 2017-2028North America Market Analysis, Insights and Forecast, 2017-2028Europe Market Analysis, Insights and Forecast, 2017-2028Asia Pacific Market Analysis, Insights and Forecast, 2017-2028The Middle East and Africa Market Analysis, Insights and Forecast, 2017-2028Latin America Market Analysis, Insights and Forecast, 2017-2028Competitive LandscapeGlobal Multiple Myeloma Market Revenue Growth, Industry Share Analysis, By Key Players, 2021Company ProfilesConclusionPurchase Full Report at :https://www.

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight

Ankit Nigam 2020-10-23

the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.

In the case of China, higher usage of thalidomide based regimen found in the first-line settingAmong emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to result in significant revenues owing to promising results, one-time dosing and premium pricing in heavily pretreated patientsKey Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc.Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-marketThough Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States.

It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role.

Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs.

Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly.

Report includes exhaustive analysis of Multiple Myeloma Pipeline TherapiesIdecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bioVenetoclax (Venclexta, Venclyxto): AbbVieJNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and DevelopmentKeytruda (pembrolizumab): NovartisMelflufen (melphalan flufenamide): OncopeptidesCetrelimab (JNJ-63723283): Janssen Research and DevelopmentREGN5458: Regeneron PharmaceuticalsIberdomide: CelgeneNY-ESO-1 C259 T Cells: GlaxoSmithKlineBraftovi (encorafenib): PfizerJCARH125: Celgene CorporationFelzartamab (MOR202): I-Mab BiopharmaChidamide (Epidaza): Shenzhen Chipscreen BioscienceThe past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times.

Multiple Myeloma Treatment Market Trends, Share, Size, Type, Application and Forecast To 2027

anna grace 2022-02-17

As per Multiple Myeloma Research Foundation, multiple myeloma generally occurs in bone marrow particularly located in the pelvic bones, spine, ribs, and the area of the hips and shoulders. com/sample_request/6818Multiple Myeloma Treatment Market Trends SegmentationThe global multiple myeloma treatment is segmented on the basis of treatment types and end users. The end users in the global Multiple Myeloma Treatment Market Trends include hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others. Competitive LandscapeThe key vendors competing in the global Multiple Myeloma Treatment Market Trends include Janssen Biotech, Inc. com/reports/multiple-myeloma-treatment-market-6818About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

Report on Multiple Myeloma Therapeutics Market Research 2028 - Value Market Research

Betty Johns 2022-03-01

COVID-19 Impact Analysis on Multiple Myeloma Therapeutics Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2022-2028. Get more information on "Global Multiple Myeloma Therapeutics Market Research Report" by requesting FREE Sample Copy at https://www. Browse Global Multiple Myeloma Therapeutics Market Research Report with detailed TOC at https://www. By Product Type· Chemotherapy· Radiation· Stem Cell Transplant· Other Supportive TreatmentsBy End Users/Applications· Hospitals· Clinics· OthersRegional AnalysisThis section covers the regional outlook, which accentuates current and future demand for the Multiple Myeloma Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Purchase Complete Global Multiple Myeloma Therapeutics Market Research Report at https://www.

Multiple Myeloma Treatment Market Competitive Landscape, Growth Factors, Revenue Analysis Till 2027

Jason Miller 2022-04-21

com/sample_request/6818As per Multiple Myeloma Research Foundation, multiple myeloma generally occurs in bone marrow particularly located in the pelvic bones, spine, ribs, and the area of the hips and shoulders. SegmentationThe global multiple myeloma treatment is segmented on the basis of treatment types and end users. The end users in the global multiple myeloma treatment market include hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others. Competitive LandscapeThe key vendors competing in the global multiple myeloma treatment market include Janssen Biotech, Inc. com/reports/multiple-myeloma-treatment-market-6818About Market Research Future:At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

Multiple Myeloma Therapeutics Market Analysis Report and Opportunities Upto 2028

Chetna Noor 2023-03-29

WHO TO FOLLOW